Cencora said it completed the acquisition of Retina Consultants of America (RCA) on January 2, 2025, making RCA a subsidiary, and acquired an interest of approximately 85% in RCA. Certain RCA physicians and members of the management team retained a minority equity interest.

1. 01

   Cencora said it completed the acquisition of Retina Consultants of America (RCA) on January 2, 2025, making RCA a subsidiary, and acquired an interest of approximately 85% in RCA. Certain RCA physicians and members of the management team retained a minority equity interest.

2. 02

   The company said its cash outlay at closing was $4.4 billion, which is subject to a customary post-closing purchase price adjustment.

3. 03

   The company said the cash outlay at closing was $4.4 billion, after reflecting the equity rollover, the cash capitalization of RCA that Cencora made, the payment of transaction fees and expenses, and the repayment of debt.

4. 04

   Cencora said it raised its fiscal 2025 adjusted diluted EPS outlook to $15.15 to $15.45 from the previous $14.80 to $15.10, reflecting the expected contribution from the RCA acquisition closing and continued momentum in its U.S. Healthcare Solutions segment.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.